Cargando…

Optofluidic device for the quantification of circulating tumor cells in breast cancer

Metastatic cancer patients require a continuous monitoring during the sequential treatment cycles to carefully evaluate their disease evolution. Repetition of biopsies is very invasive and not always feasible. Herein, we design and demonstrate a 3D-flow focusing microfluidic device, where all optics...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedrol, Eric, Garcia-Algar, Manuel, Massons, Jaume, Nazarenus, Moritz, Guerrini, Luca, Martínez, Javier, Rodenas, Airan, Fernandez-Carrascal, Ana, Aguiló, Magdalena, Estevez, Laura G., Calvo, Isabel, Olano-Daza, Ana, Garcia-Rico, Eduardo, Díaz, Francesc, Alvarez-Puebla, Ramon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473916/
https://www.ncbi.nlm.nih.gov/pubmed/28623262
http://dx.doi.org/10.1038/s41598-017-04033-9
_version_ 1783244373180284928
author Pedrol, Eric
Garcia-Algar, Manuel
Massons, Jaume
Nazarenus, Moritz
Guerrini, Luca
Martínez, Javier
Rodenas, Airan
Fernandez-Carrascal, Ana
Aguiló, Magdalena
Estevez, Laura G.
Calvo, Isabel
Olano-Daza, Ana
Garcia-Rico, Eduardo
Díaz, Francesc
Alvarez-Puebla, Ramon A.
author_facet Pedrol, Eric
Garcia-Algar, Manuel
Massons, Jaume
Nazarenus, Moritz
Guerrini, Luca
Martínez, Javier
Rodenas, Airan
Fernandez-Carrascal, Ana
Aguiló, Magdalena
Estevez, Laura G.
Calvo, Isabel
Olano-Daza, Ana
Garcia-Rico, Eduardo
Díaz, Francesc
Alvarez-Puebla, Ramon A.
author_sort Pedrol, Eric
collection PubMed
description Metastatic cancer patients require a continuous monitoring during the sequential treatment cycles to carefully evaluate their disease evolution. Repetition of biopsies is very invasive and not always feasible. Herein, we design and demonstrate a 3D-flow focusing microfluidic device, where all optics are integrated into the chip, for the fluorescence quantification of CTCs in real samples. To test the chip performance, two cell membrane targets, the epithelial cell adhesion molecule, EpCAM, and the receptor tyrosine-protein kinase, HER2, are selected. The efficiency of the platform is demonstrated on cell lines and in a variety of healthy donors and metastatic-breast cancer patients.
format Online
Article
Text
id pubmed-5473916
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-54739162017-06-21 Optofluidic device for the quantification of circulating tumor cells in breast cancer Pedrol, Eric Garcia-Algar, Manuel Massons, Jaume Nazarenus, Moritz Guerrini, Luca Martínez, Javier Rodenas, Airan Fernandez-Carrascal, Ana Aguiló, Magdalena Estevez, Laura G. Calvo, Isabel Olano-Daza, Ana Garcia-Rico, Eduardo Díaz, Francesc Alvarez-Puebla, Ramon A. Sci Rep Article Metastatic cancer patients require a continuous monitoring during the sequential treatment cycles to carefully evaluate their disease evolution. Repetition of biopsies is very invasive and not always feasible. Herein, we design and demonstrate a 3D-flow focusing microfluidic device, where all optics are integrated into the chip, for the fluorescence quantification of CTCs in real samples. To test the chip performance, two cell membrane targets, the epithelial cell adhesion molecule, EpCAM, and the receptor tyrosine-protein kinase, HER2, are selected. The efficiency of the platform is demonstrated on cell lines and in a variety of healthy donors and metastatic-breast cancer patients. Nature Publishing Group UK 2017-06-16 /pmc/articles/PMC5473916/ /pubmed/28623262 http://dx.doi.org/10.1038/s41598-017-04033-9 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Pedrol, Eric
Garcia-Algar, Manuel
Massons, Jaume
Nazarenus, Moritz
Guerrini, Luca
Martínez, Javier
Rodenas, Airan
Fernandez-Carrascal, Ana
Aguiló, Magdalena
Estevez, Laura G.
Calvo, Isabel
Olano-Daza, Ana
Garcia-Rico, Eduardo
Díaz, Francesc
Alvarez-Puebla, Ramon A.
Optofluidic device for the quantification of circulating tumor cells in breast cancer
title Optofluidic device for the quantification of circulating tumor cells in breast cancer
title_full Optofluidic device for the quantification of circulating tumor cells in breast cancer
title_fullStr Optofluidic device for the quantification of circulating tumor cells in breast cancer
title_full_unstemmed Optofluidic device for the quantification of circulating tumor cells in breast cancer
title_short Optofluidic device for the quantification of circulating tumor cells in breast cancer
title_sort optofluidic device for the quantification of circulating tumor cells in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473916/
https://www.ncbi.nlm.nih.gov/pubmed/28623262
http://dx.doi.org/10.1038/s41598-017-04033-9
work_keys_str_mv AT pedroleric optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT garciaalgarmanuel optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT massonsjaume optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT nazarenusmoritz optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT guerriniluca optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT martinezjavier optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT rodenasairan optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT fernandezcarrascalana optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT aguilomagdalena optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT estevezlaurag optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT calvoisabel optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT olanodazaana optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT garciaricoeduardo optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT diazfrancesc optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer
AT alvarezpueblaramona optofluidicdeviceforthequantificationofcirculatingtumorcellsinbreastcancer